Regeneron has one of the best pipeline of new molecules. Despite the criticism the author believes there is significant upside.
The author has purchased Regeneron (REGN) at $88.24.
Subscribe to:
Post Comments (Atom)
"Investments in lockstep with market moves"
2 comments:
This company has tremendous potential regarding Eyelea (already approved) and the upcoming cholestrol drug.
Some investors are into biotech I am not one of them.
Post a Comment